Pharma Reaserch Prod Co Ltd (214450) - Total Assets
Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) holds total assets worth ₩1.04 Trillion KRW (≈ $707.43 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Pharma Reaserch Prod Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Pharma Reaserch Prod Co Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Pharma Reaserch Prod Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Pharma Reaserch Prod Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Pharma Reaserch Prod Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Pharma Reaserch Prod Co Ltd's total assets of ₩1.04 Trillion consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 16.8% |
| Accounts Receivable | ₩44.49 Billion | 4.3% |
| Inventory | ₩82.70 Billion | 7.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩18.99 Billion | 1.8% |
| Goodwill | ₩12.46 Billion | 1.2% |
Asset Composition Trend (2015–2025)
This chart illustrates how Pharma Reaserch Prod Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Pharma Reaserch Prod Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharma Reaserch Prod Co Ltd's current assets represent 72.8% of total assets in 2025, a decrease from 79.3% in 2015.
- Cash Position: Cash and equivalents constituted 16.8% of total assets in 2025, up from 8.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 7.9% of total assets.
Pharma Reaserch Prod Co Ltd Competitors by Total Assets
Key competitors of Pharma Reaserch Prod Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Pharma Reaserch Prod Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.88 | 6.70 | 3.43 |
| Quick Ratio | 6.13 | 6.00 | 2.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩649.07 Billion | ₩471.72 Billion | ₩98.08 Billion |
Pharma Reaserch Prod Co Ltd - Advanced Valuation Insights
This section examines the relationship between Pharma Reaserch Prod Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.38 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 22.0% |
| Total Assets | ₩1.04 Trillion |
| Market Capitalization | $2.10 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pharma Reaserch Prod Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pharma Reaserch Prod Co Ltd's assets grew by 22.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pharma Reaserch Prod Co Ltd (2015–2025)
The table below shows the annual total assets of Pharma Reaserch Prod Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.04 Trillion ≈ $707.43 Million |
+21.99% |
| 2024-12-31 | ₩855.70 Billion ≈ $579.90 Million |
+59.86% |
| 2023-12-31 | ₩535.28 Billion ≈ $362.75 Million |
+11.97% |
| 2022-12-31 | ₩478.06 Billion ≈ $323.97 Million |
+11.79% |
| 2021-12-31 | ₩427.65 Billion ≈ $289.81 Million |
+33.71% |
| 2020-12-31 | ₩319.83 Billion ≈ $216.75 Million |
+18.49% |
| 2019-12-31 | ₩269.93 Billion ≈ $182.92 Million |
+4.55% |
| 2018-12-31 | ₩258.19 Billion ≈ $174.97 Million |
+36.58% |
| 2017-12-31 | ₩189.03 Billion ≈ $128.11 Million |
+5.41% |
| 2016-12-31 | ₩179.33 Billion ≈ $121.53 Million |
+5.92% |
| 2015-12-31 | ₩169.31 Billion ≈ $114.74 Million |
-- |
About Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more